PMID- 30756511
OWN - NLM
STAT- MEDLINE
DCOM- 20200529
LR  - 20221207
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Linking)
VI  - 21
IP  - 6
DP  - 2019 Jun
TI  - Relative contribution of basal and postprandial hyperglycaemia stratified by 
      HbA1c categories before and after treatment intensification with dulaglutide.
PG  - 1365-1372
LID - 10.1111/dom.13662 [doi]
AB  - AIM: To assess the effect of dulaglutide on the relative contribution of basal 
      hyperglycaemia (BHG) and postprandial hyperglycaemia (PPHG) to overall 
      hyperglycaemia across HbA1c categories in patients with type 2 diabetes. METHODS: 
      Data from five phase 3 studies (N = 673) were pooled to assess the change in 
      relative contributions of BHG and PPHG to overall hyperglycaemia across different 
      HbA1c categories after 6 months of treatment intensification with dulaglutide 1.5 
      mg as monotherapy or with 1 or 2 oral medication(s) in patients with type 2 
      diabetes. BHG and PPHG were calculated using the area under the curve (AUC) of 
      7-point self-monitored plasma glucose concentration profiles. As a secondary 
      objective, relative contribution of BHG and PPHG for dulaglutide versus 
      liraglutide, exenatide BID and insulin glargine was assessed by individual 
      studies at 6 months. RESULTS: In pooled data, after 6 months of treatment 
      intensification with dulaglutide 1.5 mg, there was a significant reduction from 
      baseline in overall hyperglycaemia (AUC(overall) ) [(mean +/- SE) 
      -466.31 +/- 18.32 mg*h/dL (P < 0.001)], BHG (AUC(basal) ) [(mean +/- SE) 
      -371.46 +/- 16.36 mg*h/dL (P < 0.001)] and PPHG (AUC(postprandial) ) [(mean +/- SE) 
      -94.84 +/- 7.97 mg*h/dL (P < 0.001)]. At baseline, relative contributions of BHG 
      increased and PPHG decreased with increasing HbA1c levels. This pattern was 
      maintained at 6 months, even as overall glycaemia improved with decreasing HbA1c 
      values. CONCLUSIONS: In patients with type 2 diabetes, dulaglutide reduces HbA1c 
      by lowering both basal and postprandial hyperglycaemia across various HbA1c 
      levels.
CI  - (c) 2019 John Wiley & Sons Ltd.
FAU - Umpierrez, Guillermo
AU  - Umpierrez G
AUID- ORCID: 0000-0002-3252-5026
AD  - Department of Medicine, Emory University, Atlanta, Georgia.
FAU - Pantalone, Kevin M
AU  - Pantalone KM
AUID- ORCID: 0000-0002-3897-4551
AD  - Department of Endocrinology, Cleveland Clinic, Cleveland, Ohio.
FAU - Atisso, Charles M
AU  - Atisso CM
AD  - Lilly USA, LLC, Indianapolis, Indiana.
FAU - Lando, Laura Fernandez
AU  - Lando LF
AUID- ORCID: 0000-0002-0969-6214
AD  - Lilly USA, LLC, Indianapolis, Indiana.
FAU - Patel, Hiren
AU  - Patel H
AUID- ORCID: 0000-0003-2463-4916
AD  - Lilly USA, LLC, Indianapolis, Indiana.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190318
PL  - England
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Immunoglobulin Fc Fragments)
RN  - 0 (Insulin)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 0 (hemoglobin A1c protein, human)
RN  - 62340-29-8 (Glucagon-Like Peptides)
RN  - WTT295HSY5 (dulaglutide)
SB  - IM
MH  - Aged
MH  - Blood Glucose/drug effects
MH  - Diabetes Mellitus, Type 2/*drug therapy/metabolism
MH  - Fasting/physiology
MH  - Female
MH  - Glucagon-Like Peptides/administration & dosage/*analogs & 
      derivatives/pharmacology/therapeutic use
MH  - *Glycated Hemoglobin/analysis/metabolism
MH  - Humans
MH  - Hyperglycemia/blood/drug therapy
MH  - *Hypoglycemic Agents/administration & dosage/pharmacology/therapeutic use
MH  - *Immunoglobulin Fc Fragments/administration & dosage/pharmacology/therapeutic use
MH  - Insulin/blood
MH  - Male
MH  - Middle Aged
MH  - Postprandial Period/physiology
MH  - *Recombinant Fusion Proteins/administration & dosage/pharmacology/therapeutic use
OTO - NOTNLM
OT  - GLP-1 RAs
OT  - basal insulin
OT  - dulaglutide
OT  - glycaemic control
OT  - type 2 diabetes
EDAT- 2019/02/14 06:00
MHDA- 2020/05/30 06:00
CRDT- 2019/02/14 06:00
PHST- 2018/11/29 00:00 [received]
PHST- 2019/01/28 00:00 [revised]
PHST- 2019/02/09 00:00 [accepted]
PHST- 2019/02/14 06:00 [pubmed]
PHST- 2020/05/30 06:00 [medline]
PHST- 2019/02/14 06:00 [entrez]
AID - 10.1111/dom.13662 [doi]
PST - ppublish
SO  - Diabetes Obes Metab. 2019 Jun;21(6):1365-1372. doi: 10.1111/dom.13662. Epub 2019 
      Mar 18.